Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 44
Filtrer
1.
Eur Urol Oncol ; 6(6): 597-603, 2023 12.
Article de Anglais | MEDLINE | ID: mdl-37005214

RÉSUMÉ

BACKGROUND: Radiation therapy (RT) is an alternative to radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). OBJECTIVE: To analyze predictors of complete response (CR) and survival after RT for MIBC. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter retrospective study of 864 patients with nonmetastatic MIBC who underwent curative-intent RT from 2002 to 2018. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Regression models were used to explore prognostic factors associated with CR, cancer-specific survival (CSS), and overall survival (OS). RESULTS AND LIMITATIONS: The median patient age was 77 yr and median follow-up was 34 mo. Disease stage was cT2 in 675 patients (78%) and cN0 in 766 (89%). Neoadjuvant chemotherapy (NAC) was given to 147 patients (17%) and concurrent chemotherapy to 542 (63%). A CR was experienced by 592 patients (78%). cT3-4 stage (odds ratio [OR] 0.43, 95% confidence interval [CI] 0.29-0.63; p < 0.001) and hydronephrosis (OR 0.50, 95% CI 034-0.74; p = 0.001) were significantly associated with lower CR. The 5-yr survival rates were 63% for CSS and 49% for OS. Higher cT stage (HR 1.93, 95% CI 1.46-2.56; p < 0.001), carcinoma in situ (HR 2.10, 95% CI 1.25-3.53; p = 0.005), hydronephrosis (HR 2.36, 95% CI 1.79-3.10; p < 0.001), NAC use (HR 0.66, 95% CI 0.46-0.95; p = 0.025), and whole-pelvis RT (HR 0.66, 95% CI 0.51-0.86; p = 0.002) were independently associated with CSS; advanced age (HR 1.03, 95% CI 1.01-1.05; p = 0.001), worse performance status (HR 1.73, 95% CI 1.34-2.22; p < 0.001), hydronephrosis (HR 1.50, 95% CI 1.17-1.91; p = 0.001), NAC use (HR 0.69, 95% CI 0.49-0.97; p = 0.033), whole-pelvis RT (HR 0.64, 95% CI 0.51-0.80; p < 0.001), and being surgically unfit (HR 1.42, 95% CI 1.12-1.80; p = 0.004) were associated with OS. The study is limited by the heterogeneity of different treatment protocols. CONCLUSIONS: RT for MIBC yields a CR in most patients who elect for curative-intent bladder preservation. The benefit of NAC and whole-pelvis RT require prospective trial validation. PATIENT SUMMARY: We investigated outcomes for patients with muscle-invasive bladder cancer treated with curative-intent radiation therapy as an alternative to surgical removal of the bladder. The benefit of chemotherapy before radiotherapy and whole-pelvis radiation (bladder plus the pelvis lymph nodes) needs further study.


Sujet(s)
Hydronéphrose , Tumeurs de la vessie urinaire , Humains , Études rétrospectives , Études prospectives , Survie sans rechute , Tumeurs de la vessie urinaire/radiothérapie , Tumeurs de la vessie urinaire/traitement médicamenteux , Muscles/anatomopathologie
2.
Urol Oncol ; 39(11): 786.e1-786.e8, 2021 11.
Article de Anglais | MEDLINE | ID: mdl-33846085

RÉSUMÉ

INTRODUCTION: Radiation therapy (XRT) has been investigated as a possible treatment for high-risk non-muscle invasive bladder cancer (NMIBC) with the goal of bladder preservation, especially with the ongoing Bacillus Calmette-Guerin (BCG) shortage. Yet, little is known about the clinical efficacy and the quality of evidence supporting XRT for NMIBC. Herein, we performed a systematic review and meta-analysis to evaluate XRT in the treatment of patients with high-risk NMIBC. METHODS: Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE, and Web of Science were searched for high-risk NMIBC (high grade T1, T1/Ta with associated risk features: carcinoma in-situ (CIS), multifocality, > 5cm in diameter, and/or multiple recurrences) treated with primary XRT. Outcomes evaluated were recurrence-free survival (RFS), cancer-specific-survival (CSS), overall survival (OS), and salvage cystectomy and progression to metastatic disease rates. A meta-analysis was performed to assess outcomes for XRT in NMIBC. RESULTS: Overall,13 studies including 746 patients met the search criteria. The 5-year rates of RFS, CSS and OS were 54% (95% CI = 38% - 70%), 86% (95% CI = 80% - 92%), and 72% (95% CI = 64% - 79%). Notably, 13% of patients proceeded to salvage radical cystectomy and 9% developed metastatic disease. All studies were of poor quality, comprising single institution and retrospective studies with only one clinical trial. CONCLUSION: XRT for high-risk NMIBC provides some degree of oncologic control, although distant progression was noted. In the setting of the low-quality evidence, a prospective clinical trial is needed to clearly define the risks and benefits of this approach.


Sujet(s)
Tumeurs de la vessie urinaire/radiothérapie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Mâle , Adulte d'âge moyen
3.
Int. braz. j. urol ; 47(1): 93-99, Jan.-Feb. 2021. tab, graf
Article de Anglais | LILACS | ID: biblio-1134320

RÉSUMÉ

ABSTRACT Hypothesis: Endoclip can be used as fiducial marker in urology. Objective: To assess the feasibility, cost effectiveness and reliability of endoclips as novel fiducial markers in precision radiotherapy, as part of a trimodality bladder-preserving treatment (TBPT) of muscle-invasive bladder carcinoma. Materials and Methods: This retrospective study was performed at Weifang People's Hospital (Weifang, China) from January 2015 to June 2018. A total of 15 patients underwent TBPT. Endoclips were applied to healthy edges of the resected bladder wall as novel fiducial markers. Radio-sensitizing chemotherapy and routine precision radiotherapy were given. The number and position of the endoclips during radiotherapy sessions were monitored. Complications and tumor recurrence were analyzed. Results: The mean age (±standard deviation) of the patients was 67±10 years (range 46-79). There were 3 females and 12 males. Forty-nine endoclips were applied in all patients (3.3±0.8). The tumor was completely visibly resected in all patients. The number of endoclips remained the same through the planned last radiotherapy session (3.3±0.8), i.e., none were lost. All endoclips were removed after the last radiotherapy session. The average number of follow-up months was 38.9±13.2 (range 11-52). There were no procedure-related complications at discharge or follow-up. At one-year, overall recurrence-free survival was 93.3%. Two patients had recurrences at 18 months and 10 months after TBPT, respectively, and salvage radical cystectomy was performed with no further recurrences. Another patient died due to metastasis 9 months after the completion of therapy. Conclusions: Endoclips are reliable, safe and cost-effective as novel fiducial markers in precision-radiotherapy post-TBPT.


Sujet(s)
Humains , Mâle , Femelle , Sujet âgé , Tumeurs de la vessie urinaire/chirurgie , Tumeurs de la vessie urinaire/radiothérapie , Carcinomes , Vessie urinaire , Cystectomie , Chine , Études de faisabilité , Reproductibilité des résultats , Études rétrospectives , Résultat thérapeutique , Association thérapeutique , Marques de positionnement , Adulte d'âge moyen , Muscles , Invasion tumorale , Récidive tumorale locale
4.
Int Braz J Urol ; 47(1): 93-99, 2021.
Article de Anglais | MEDLINE | ID: mdl-32271508

RÉSUMÉ

HYPOTHESIS: Endoclip can be used as fiducial marker in urology. OBJECTIVE: To assess the feasibility, cost effectiveness and reliability of endoclips as novel fiducial markers in precision radiotherapy, as part of a trimodality bladder-preserving treatment (TBPT) of muscle-invasive bladder carcinoma. MATERIALS AND METHODS: This retrospective study was performed at Weifang People's Hospital (Weifang, China) from January 2015 to June 2018. A total of 15 patients underwent TBPT. Endoclips were applied to healthy edges of the resected bladder wall as novel fiducial markers. Radio-sensitizing chemotherapy and routine precision radiotherapy were given. The number and position of the endoclips during radiotherapy sessions were monitored. Complications and tumor recurrence were analyzed. RESULTS: The mean age (±standard deviation) of the patients was 67±10 years (range 46-79). There were 3 females and 12 males. Forty-nine endoclips were applied in all patients (3.3±0.8). The tumor was completely visibly resected in all patients. The number of endoclips remained the same through the planned last radiotherapy session (3.3±0.8), i.e., none were lost. All endoclips were removed after the last radiotherapy session. The average number of follow-up months was 38.9±13.2 (range 11-52). There were no procedure-related complications at discharge or follow-up. At one-year, overall recurrence-free survival was 93.3%. Two patients had recurrences at 18 months and 10 months after TBPT, respectively, and salvage radical cystectomy was performed with no further recurrences. Another patient died due to metastasis 9 months after the completion of therapy. CONCLUSIONS: Endoclips are reliable, safe and cost-effective as novel fiducial markers in precision-radiotherapy post-TBPT.


Sujet(s)
Carcinomes , Tumeurs de la vessie urinaire , Sujet âgé , Chine , Association thérapeutique , Cystectomie , Études de faisabilité , Femelle , Marques de positionnement , Humains , Mâle , Adulte d'âge moyen , Muscles , Invasion tumorale , Récidive tumorale locale , Reproductibilité des résultats , Études rétrospectives , Résultat thérapeutique , Vessie urinaire , Tumeurs de la vessie urinaire/radiothérapie , Tumeurs de la vessie urinaire/chirurgie
5.
Clin Transl Oncol ; 21(12): 1707-1711, 2019 Dec.
Article de Anglais | MEDLINE | ID: mdl-30949931

RÉSUMÉ

PURPOSE: Radiotherapy-induced dysfunction of the gastrointestinal tract is common in cancer patients and has a significant impact on their quality of life. In this study, we investigated the prevalence of breakthrough cancer pain (BTcP) in patients undergoing 3D pelvic radiotherapy and who had proctalgia. METHODS: This observational, multicenter, cross-sectional epidemiological study was performed in 13 Spanish hospitals. Data were obtained on the presence and characteristics of BTcP, demographics, common comorbidities, and treatments prescribed to the patients. RESULTS: The prevalence of BTcP in patients undergoing pelvic 3D external radiotherapy with proctalgia (N = 105) was 48.6% (95% CI 39.0-58.1%). BTcP was further characterized in 59 patients. The mean (± SD) intensity of the BTcP episodes was 7.45 ± 1.47 in a visual analog scale. We found several statistically significant associations between the descriptive variables of BTcP with demographic and clinical variables associated with the tumor or the patient, such as an increased number of BTcP episodes per day depending on the presence or absence of diabetes (p = 0.001, Chi-square) or time to the onset of pain relief depending on the location of the tumor (p = 0.019, Chi-square). Fentanyl was the drug of choice in BTcP episodes for 95% of the patients. CONCLUSIONS: This study demonstrated a high prevalence of BTcP prevalence in cancer patients undergoing pelvic 3D radiotherapy and with proctalgia. Although the variables determining the onset of BTcP are still unclear, our results could help in the design of future clinical studies addressing the treatment of BTcP in these patients.


Sujet(s)
Douleur paroxystique/épidémiologie , Douleur cancéreuse/épidémiologie , Tumeurs/radiothérapie , Douleur/épidémiologie , Radiothérapie conformationnelle/effets indésirables , Maladies du rectum/épidémiologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Tumeurs de l'anus/traitement médicamenteux , Tumeurs de l'anus/radiothérapie , Douleur paroxystique/traitement médicamenteux , Douleur paroxystique/étiologie , Douleur cancéreuse/traitement médicamenteux , Douleur cancéreuse/étiologie , Loi du khi-deux , Études transversales , Tumeurs de l'endomètre/radiothérapie , Femelle , Humains , Mâle , Adulte d'âge moyen , Tumeurs/traitement médicamenteux , Douleur/traitement médicamenteux , Prévalence , Tumeurs de la prostate/traitement médicamenteux , Tumeurs de la prostate/radiothérapie , Dosimétrie en radiothérapie , Maladies du rectum/traitement médicamenteux , Tumeurs du rectum/traitement médicamenteux , Tumeurs du rectum/radiothérapie , Espagne/épidémiologie , Tumeurs de la vessie urinaire/traitement médicamenteux , Tumeurs de la vessie urinaire/radiothérapie , Tumeurs du col de l'utérus/radiothérapie
6.
Int. braz. j. urol ; 45(2): 299-305, Mar.-Apr. 2019. tab
Article de Anglais | LILACS | ID: biblio-1002199

RÉSUMÉ

ABSTRACT Purpose: To describe the clinical characteristics, treatment patterns, and outcomes in patients with small cell bladder cancer at our institution, including those who received prophylactic cranial irradiation (PCI) for the prevention of intracranial recurrence. Materials and Methods: Patients with small cell bladder cancer treated at a single institution between January 1990 and August 2015 were identified and analyzed retrospectively for demographics, tumor stage, treatment, and overall survival. Results: Of 44 patients diagnosed with small cell bladder cancer, 11 (25%) had metastatic disease at the time of presentation. Treatment included systemic chemotherapy (70%), radical surgery (59%), and local radiation (39%). Six patients (14%) received PCI. Median overall survival was 10 months (IQR 4 - 41). Patients with extensive disease had worse overall survival than those with organ confined disease (8 months vs. 36 months, respectively, p = 0.04). Among those who received PCI, 33% achieved 5 - year survival. Conclusion: Outcomes for patients with small cell bladder cancer remain poor. Further research is indicated to determine if PCI increases overall survival in small call bladder cancer patients, especially those with extensive disease who respond to chemotherapy.


Sujet(s)
Humains , Mâle , Sujet âgé , Sujet âgé de 80 ans ou plus , Tumeurs de la vessie urinaire/radiothérapie , Irradiation crânienne/méthodes , Carcinome à petites cellules/radiothérapie , Tumeurs de la vessie urinaire/mortalité , Tumeurs de la vessie urinaire/anatomopathologie , Analyse de survie , Études rétrospectives , Carcinome à petites cellules/mortalité , Carcinome à petites cellules/anatomopathologie , Carcinome pulmonaire à petites cellules/anatomopathologie , Carcinome pulmonaire à petites cellules/radiothérapie , Tumeurs du poumon/mortalité , Tumeurs du poumon/anatomopathologie , Tumeurs du poumon/radiothérapie
7.
Int Braz J Urol ; 45(2): 299-305, 2019.
Article de Anglais | MEDLINE | ID: mdl-30521161

RÉSUMÉ

PURPOSE: To describe the clinical characteristics, treatment patterns, and outcomes in patients with small cell bladder cancer at our institution, including those who received prophylactic cranial irradiation (PCI) for the prevention of intracranial recurrence. MATERIALS AND METHODS: Patients with small cell bladder cancer treated at a single institution between January 1990 and August 2015 were identified and analyzed retrospectively for demographics, tumor stage, treatment, and overall survival. RESULTS: Of 44 patients diagnosed with small cell bladder cancer, 11 (25%) had metastatic disease at the time of presentation. Treatment included systemic chemotherapy (70%), radical surgery (59%), and local radiation (39%). Six patients (14%) received PCI. Median overall survival was 10 months (IQR 4 - 41). Patients with extensive disease had worse overall survival than those with organ confined disease (8 months vs. 36 months, respectively, p = 0.04). Among those who received PCI, 33% achieved 5 - year survival. CONCLUSION: Outcomes for patients with small cell bladder cancer remain poor. Further research is indicated to determine if PCI increases overall survival in small call bladder cancer patients, especially those with extensive disease who respond to chemotherapy.


Sujet(s)
Carcinome à petites cellules/radiothérapie , Irradiation crânienne , Tumeurs de la vessie urinaire/radiothérapie , Sujet âgé , Sujet âgé de 80 ans ou plus , Carcinome à petites cellules/mortalité , Carcinome à petites cellules/anatomopathologie , Irradiation crânienne/méthodes , Humains , Tumeurs du poumon/mortalité , Tumeurs du poumon/anatomopathologie , Tumeurs du poumon/radiothérapie , Mâle , Études rétrospectives , Carcinome pulmonaire à petites cellules/anatomopathologie , Carcinome pulmonaire à petites cellules/radiothérapie , Analyse de survie , Tumeurs de la vessie urinaire/mortalité , Tumeurs de la vessie urinaire/anatomopathologie
8.
J Cancer Res Clin Oncol ; 144(3): 469-482, 2018 Mar.
Article de Anglais | MEDLINE | ID: mdl-29305710

RÉSUMÉ

PURPOSE: Trimodal therapy is a reasonable bladder-preserving option to radical cystectomy. However, many tumors are radioresistive. In this sense, the identification of new prognostic and predictive biomarkers that allow the selection of patients with better responses to radiation therapy would improve outcomes. With the aim of using ecto-5'-nucleotidase/CD73 as a predictive biomarker, the role of this enzyme in the context of radiotherapy in T24 human bladder cancer cell line was investigated. METHODS: T24 cell line was exposure to a single dose of radiation (4 Gray) and trypan blue assay (pharmacological assays of viability/cumulative population doubling), flow cytometry (cell cycle/cell death/active caspase-3/ecto-5'-nucleotidase/CD73 protein staining), DAPI staining (nuclear morphometric assay), RT-PCR and real-time PCR, malachite green method (ectonucleotidase enzymatic assay), and HPLC (analysis of AMP metabolism) were carried out. T24 cell line in which ecto-5'-nucleotidase/CD73 has been completely silenced (5'KO) was also used. RESULTS: The exposure of T24 cell line to a single dose (4 Gray) of radiation-induced cell death and triggered a transitory increase in ecto-5'-nucleotidase/CD73 expression, increased ectonucleotidase activity, and led to adenosine and inosine accumulation in the extracellular medium. Pharmacological inhibition or knocking out ecto-5'-nucleotidase/CD73 rescued cells' proliferative capacity, reducing their sensitivity to radiation. CONCLUSION: Our findings show that the induction of ecto-5'-nucleotidase/CD73 by radiation contributes to the radiosensitivity of T24 cell line.


Sujet(s)
5'-Nucleotidase/physiologie , Radiotolérance/génétique , Tumeurs de la vessie urinaire/anatomopathologie , Tumeurs de la vessie urinaire/radiothérapie , 5'-Nucleotidase/génétique , 5'-Nucleotidase/métabolisme , Lignée cellulaire tumorale , Prolifération cellulaire/génétique , Prolifération cellulaire/effets des radiations , Protéines liées au GPI/génétique , Protéines liées au GPI/métabolisme , Protéines liées au GPI/physiologie , Régulation de l'expression des gènes codant pour des enzymes/effets des radiations , Régulation de l'expression des gènes tumoraux/effets des radiations , Techniques de knock-down de gènes , Humains , Dose de rayonnement , Tumeurs de la vessie urinaire/génétique , Tumeurs de la vessie urinaire/métabolisme
9.
J Cell Biochem ; 119(7): 5402-5412, 2018 07.
Article de Anglais | MEDLINE | ID: mdl-29363820

RÉSUMÉ

Conservative treatment for invasive bladder cancer (BC) involves a complete transurethral tumor resection combined with chemotherapy (CT) and radiotherapy (RT). The major obstacles of chemo-radiotherapy are the addition of the toxicities of RT and CT, and the recurrence due to RT and CT resistances. The flavonoid Silybin (Sb) inhibits pathways involved in cell survival and resistance mechanisms, therefore the purpose of this paper was to study in vitro and in vivo, the ability of Sb to improve the response to RT, in two murine BC cell lines, with different levels of invasiveness, placing emphasis on radio-sensitivity, and pathways involved in radio-resistance and survival. In vitro, Sb radio-sensitized murine invasive cells through the inhibition of RT-induced NF-κB and PI3K pathways, and the increase of oxidative stress, while non-invasive cells did not show to be sensitized. In vivo, Sb improved RT-response and overall survival in invasive murine tumors. As Sb is already being tested in clinical trials for other urological cancers and it improves RT-response in invasive BC, these results could have translational relevance, supporting further research.


Sujet(s)
Antinéoplasiques d'origine végétale/pharmacologie , Rayons gamma , Radiosensibilisants/pharmacologie , Silibinine/pharmacologie , Tumeurs de la vessie urinaire/radiothérapie , Animaux , Survie cellulaire/effets des médicaments et des substances chimiques , Survie cellulaire/effets des radiations , Souris , Souris de lignée C57BL , Invasion tumorale , Cellules cancéreuses en culture , Tumeurs de la vessie urinaire/traitement médicamenteux , Tumeurs de la vessie urinaire/anatomopathologie
10.
Clin Transl Oncol ; 20(7): 899-905, 2018 Jul.
Article de Anglais | MEDLINE | ID: mdl-29159793

RÉSUMÉ

PURPOSE: To report the outcomes of a cohort of very elderly muscle-invasive bladder cancer (MIBC) patients treated with contemporary 3D-conformal radiation therapy (3D-CRT) with or without concurrent chemotherapy, after transurethral resection of bladder tumor (TURBT). METHODS: From February 2010 to January 2014, a total of 41 patients older than 75 years, with T2-3 N0-1 high-grade MIBC, a Karnofsky index (KI) of at least 90% and/or a Barthel scale score of at least 95, were treated with TURBT followed by radiotherapy (RT) with or without chemotherapy, and were prospectively followed-up. RESULTS: The mean age of patients was 82 years (range 76-88). Median follow-up was 47 months for surviving patients. Mean Charlson Comorbidity Index (CCI) score was 5 points. 28 patients (68.29%) were T2N0. All received 3D-CRT to a mean dose of 60 Gy (range 48.6-66 Gy), and chemotherapy was delivered to 34 patients (83%). Cause-specific survival (CSS) was 86 and 78.8% at 1 and 5 years, respectively. Patients achieving a complete response lived longer (48 vs 14 m, p = 0.036) than those with a progressive disease, who were more likely to die from cancer than from other causes (HR 3.865, IC95% 1.562-9.562). Dead patients had a longest treatment time (mean 56.78 vs 48.91 days, p = 0.019) than survivors. CONCLUSION: RT with contemporary 3D-CRT techniques after TURBT for MIBC in elderly patients is feasible and well-tolerated. Achieving a maximal response and shortening the total radiation treatment time may improve outcomes and quality of life.


Sujet(s)
Tumeurs musculaires/radiothérapie , Récidive tumorale locale/radiothérapie , Qualité de vie , Radiothérapie conformationnelle/mortalité , Tumeurs de la vessie urinaire/radiothérapie , Sujet âgé , Sujet âgé de 80 ans ou plus , Études de cohortes , Femelle , Études de suivi , Humains , Mâle , Tumeurs musculaires/anatomopathologie , Récidive tumorale locale/anatomopathologie , Traitements préservant les organes , Pronostic , Taux de survie , Tumeurs de la vessie urinaire/anatomopathologie
11.
Nitric Oxide ; 64: 22-30, 2017 Apr 01.
Article de Anglais | MEDLINE | ID: mdl-28126499

RÉSUMÉ

BACKGROUND: A key factor contributing to radio-resistance in conservative invasive bladder cancer (BCa) treatment is tumor hypoxia and a strategy to overcome it is to trigger the production of nitric oxide (NO). On the other hand, ionizing radiation (IR) applied to a primary tumor can induce immunogenic cell death which may set off a cytotoxic immune response against the primary tumor and its metastasis. PURPOSE: To study in vitro and in vivo, the role of BCG as a local sensitizer to overcome hypoxia-associated radio-resistance through the production of NO, and as an immune-stimulator to be used in combination with IR to generate a systemic response for invasive BCa treatment. MATERIALS AND METHODS: We selected the invasive murine BCa cell line MB49-I which expresses inducible NO synthase and produces NO, cultured in vitro in 2D and 3D models, and inoculated in vivo in the subcutaneous of syngeneic mice. RESULTS: in vitro, multicellular murine invasive spheroids mimicked in vivo central tumor necrosis. BCG pre-treatment radio-sensitized spheroids through the induction of NO production, while no effect was shown in monolayers. In vivo, not only did BCG improve the local response to IR but it also decreased the metastatic spread and promoted the development of abscopal effect/rejection of a second tumor. CONCLUSION: Since BCG has already and successfully been used for the treatment of non-invasive BCa and it improves the response to ionizing radiation in invasive BCa, these results are translational relevant to be analyzed in patients with this pathology.


Sujet(s)
Vaccin BCG/usage thérapeutique , Radiosensibilisants/usage thérapeutique , Tumeurs de la vessie urinaire/radiothérapie , Animaux , Vaccin BCG/pharmacologie , Lignée cellulaire tumorale , Survie cellulaire/effets des médicaments et des substances chimiques , Survie cellulaire/effets des radiations , Souris , Souris de lignée C57BL , Nécrose , Rayonnement ionisant , Radiosensibilisants/pharmacologie , Tumeurs de la vessie urinaire/traitement médicamenteux , Tumeurs de la vessie urinaire/anatomopathologie
12.
Med Dosim ; 40(4): 372-7, 2015.
Article de Anglais | MEDLINE | ID: mdl-26323390

RÉSUMÉ

Trials of adjuvant radiation after cystectomy are under development. There are no studies comparing radiation techniques to inform trial design. This study assesses the effect on bowel and rectal dose of 3 different modalities treating 2 proposed alternative clinical target volumes (CTVs). Contours of the bowel, rectum, CTV-pelvic sidewall (common/internal/external iliac and obturator nodes), and CTV-comprehensive (CTV-pelvic sidewall plus cystectomy bed and presacral regions) were drawn on simulation images of 7 post-cystectomy patients. We optimized 3-dimensional conformal radiation (3-D), intensity-modulated radiation (IMRT), and single-field uniform dose (SFUD) scanning proton plans for each CTV. Mixed models regression was used to compare plans for bowel and rectal volumes exposed to 35% (V35%), 65% (V65%), and 95% (V95%) of the prescribed dose. For any given treatment modality, treating the larger CTV-comprehensive volume compared with treating only the CTV-pelvic sidewall nodes significantly increased rectal dose (V35% rectum, V65% rectum, and V95% rectum; p < 0.001 for all comparisons), but it did not produce significant differences in bowel dose (V95% bowel, V65% bowel, or V35% bowel). The 3-D plans, compared with both the IMRT and the SFUD plans, had a significantly greater V65% bowel and V95% bowel for each proposed CTV (p < 0.001 for all comparisons). The effect of treatment modality on rectal dosimetry differed by CTV, but it generally favored the IMRT and the SFUD plans over the 3-D plans. Comparison of the IMRT plan vs the SFUD plan yielded mixed results with no consistent advantage for the SFUD plan over the IMRT plan. Targeting a CTV that spares the cystectomy bed and presacral region may marginally improve rectal toxicity but would not be expected to improve the bowel toxicity associated with any given modality of adjuvant radiation. Using the IMRT or the SFUD plans instead of the 3-D conformal plan may improve both bowel and rectal toxicity.


Sujet(s)
Carcinomes/radiothérapie , Planification de radiothérapie assistée par ordinateur/méthodes , Tumeurs de la vessie urinaire/radiothérapie , Humains , Rectum , Études rétrospectives
14.
Int Braz J Urol ; 40(2): 190-7, 2014.
Article de Anglais | MEDLINE | ID: mdl-24856485

RÉSUMÉ

PURPOSE: To evaluate Lipiodol as a liquid, radio-opaque fiducial marker for image-guided radiation therapy (IGRT) for bladder cancer. MATERIALS AND METHODS: Between 2011 and 2012, 5 clinical T2a-T3b N0 M0 stage II-III bladder cancer patients were treated with maximal transurethral resection of a bladder tumor (TURBT) and image-guided radiation therapy (IGRT) to 64.8 Gy in 36 fractions ± concurrent weekly cisplatin-based or gemcitabine chemotherapy. Ten to 15mL Lipiodol, using 0.5mL per injection, was injected into bladder submucosa circumferentially around the entire periphery of the tumor bed immediately following maximal TURBT. The authors looked at inter-observer variability regarding the size and location of the tumor bed (CTVboost) on computed tomography scans with versus without Lipiodol. RESULTS: Median follow-up was 18 months. Lipiodol was visible on every orthogonal two-dimensional kV portal image throughout the entire, 7-week course of IGRT. There was a trend towards improved inter-observer agreement on the CTVboost with Lipiodol (p = 0.06). In 2 of 5 patients, the tumor bed based upon Lipiodol extended outside a planning target volume that would have been treated with a radiation boost based upon a cystoscopy report and an enhanced computed tomography (CT) scan for staging. There was no toxicity attributable to Lipiodol. CONCLUSIONS: Lipiodol constitutes a safe and effective fiducial marker that an urologist can use to demarcate a tumor bed immediately following maximal TURBT. Lipiodol decreases inter-observer variability in the definition of the extent and location of a tumor bed on a treatment planning CT scan for a radiation boost.


Sujet(s)
Carcinomes/radiothérapie , Produits de contraste , Huile éthiodée , Marques de positionnement , Radiothérapie guidée par l'image/méthodes , Tumeurs de la vessie urinaire/radiothérapie , Adulte , Carcinomes/imagerie diagnostique , Carcinomes/anatomopathologie , Cystoscopie/méthodes , Humains , Adulte d'âge moyen , Stadification tumorale , Biais de l'observateur , Radiographie , Valeurs de référence , Reproductibilité des résultats , Statistique non paramétrique , Résultat thérapeutique , Charge tumorale , Tumeurs de la vessie urinaire/imagerie diagnostique , Tumeurs de la vessie urinaire/anatomopathologie
15.
Int. braz. j. urol ; 40(2): 190-197, Mar-Apr/2014. tab, graf
Article de Anglais | LILACS | ID: lil-711703

RÉSUMÉ

Purpose To evaluate Lipiodol as a liquid, radio-opaque fiducial marker for image-guided radiation therapy (IGRT) for bladder cancer.Materials and Methods Between 2011 and 2012, 5 clinical T2a-T3b N0 M0 stage II-III bladder cancer patients were treated with maximal transurethral resection of a bladder tumor (TURBT) and image-guided radiation therapy (IGRT) to 64.8 Gy in 36 fractions ± concurrent weekly cisplatin-based or gemcitabine chemotherapy. Ten to 15mL Lipiodol, using 0.5mL per injection, was injected into bladder submucosa circumferentially around the entire periphery of the tumor bed immediately following maximal TURBT. The authors looked at inter-observer variability regarding the size and location of the tumor bed (CTVboost) on computed tomography scans with versus without Lipiodol.Results Median follow-up was 18 months. Lipiodol was visible on every orthogonal two-dimensional kV portal image throughout the entire, 7-week course of IGRT. There was a trend towards improved inter-observer agreement on the CTVboost with Lipiodol (p = 0.06). In 2 of 5 patients, the tumor bed based upon Lipiodol extended outside a planning target volume that would have been treated with a radiation boost based upon a cystoscopy report and an enhanced computed tomography (CT) scan for staging. There was no toxicity attributable to Lipiodol.Conclusions Lipiodol constitutes a safe and effective fiducial marker that an urologist can use to demarcate a tumor bed immediately following maximal TURBT. Lipiodol decreases inter-observer variability in the definition of the extent and location of a tumor bed on a treatment planning CT scan for a radiation boost.


Sujet(s)
Adulte , Humains , Adulte d'âge moyen , Carcinomes/radiothérapie , Produits de contraste , Huile éthiodée , Marques de positionnement , Radiothérapie guidée par l'image/méthodes , Tumeurs de la vessie urinaire/radiothérapie , Carcinomes/anatomopathologie , Carcinomes , Cystoscopie/méthodes , Stadification tumorale , Biais de l'observateur , Valeurs de référence , Reproductibilité des résultats , Statistique non paramétrique , Résultat thérapeutique , Charge tumorale , Tumeurs de la vessie urinaire/anatomopathologie , Tumeurs de la vessie urinaire
16.
Int. braz. j. urol ; 39(6): 808-816, Nov-Dec/2013. tab, graf
Article de Anglais | LILACS | ID: lil-699122

RÉSUMÉ

Objective The aim of our study was to assess short and mid-term clinical efficacy of external beam radiation therapy to achieve hemostasis in patients with bladder-cancer related gross hematuria who were unfit for surgery. We also assessed hypofractionation as a possible alternative option for more severe patients. Patients and Methods Thirty-two patients were included for hemostatic radiation therapy, with two schedules based on Eastern Cooperative Oncology Group performance status. The standard treatment was 30 Gy in 10 fractions over 2 weeks. More severe patients underwent a hypofractionated regimen, with 20 Gy in 5 fractions over a one week period. Clinical evaluation was performed at 2 weeks and 6 months. Results At 2 weeks, 69% of patients were hematuria-free. Subgroup analysis showed that 79% of patients undergoing hypofractionated regimen were hematuria-free. A total of 54% were hematuria-free with the standard regimen. Based on tumor stage, hematuria was controlled at 2 weeks for 57% of non-muscle invasive tumors and 72% of muscle-invasive tumors. After 6 months, 69% of patients had relapsed, regardless of tumor stage or therapy schedules. Conclusions Hemostatic radiotherapy is an effective option for palliative-care hematuria related to bladder cancer in patients unfit for surgery. Although it appears to be rapidly effective, its effect is of limited duration. Hypofractionation also seems to be an effective option; however larger cohorts and prospective trials are needed to evaluate its efficacy compared to standard schedules. .


Sujet(s)
Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Carcinomes/radiothérapie , Hématurie/radiothérapie , Tumeurs de la vessie urinaire/radiothérapie , Carcinomes/complications , Hématurie/étiologie , Soins palliatifs/méthodes , Protonthérapie/méthodes , Études rétrospectives , Statistique non paramétrique , Facteurs temps , Résultat thérapeutique , Tumeurs de la vessie urinaire/complications
17.
Int Braz J Urol ; 39(1): 77-82, 2013.
Article de Anglais | MEDLINE | ID: mdl-23489500

RÉSUMÉ

AIM: To evaluate acute toxicity and symptoms palliation of a weekly hypofractionated 3DCRT schedule as radical treatment in elderly patients with organ confined bladder cancer cT1-2N0. MATERIALS AND METHODS: Between February 2005 and June 2011, 58 prospectively selected patients diagnosed with organ confined bladder cancer were treated with external 3DCRT (4-field arrangement). All candidates were medically inoperable, with poor performance status, and with age ranged from 75 to 88 years (median 78). A dose of 36 Gy in 6 weekly fractions was prescribed. The primary study endpoints were the evaluation of haematuria, dysuria, frequency and pain palliation as well as the acute toxicity according to the RTOG/EORTC scale: an assessment was performed at baseline, during and 3 months after radiotherapy, while the maximum reported score was taken into account. RESULTS: The gastrointestinal acute toxicities were 13/58 (22.4%) and 5/58 (5.6%), for grade I and II respectively. The genitourinary acute toxicities were 19/58 (32.7%) and 10/58 (17.2%), for grade I and II respectively. In terms of clinical outcome, 55/58 patients (94.8%) reported palliation of haematuria, while 19 out of 58 reported no change in frequency and dysuria. All patients reported significant improvement (P < 0.01) for pain, concerning the visual analogue score before and after radiotherapy. The median progression free survival was 14 months. CONCLUSIONS: The incidence of patient-reported acute toxicity following weekly hypofractionated external 3DCRT is low while the symptom palliation compares very favorably with other reported outcomes.


Sujet(s)
Fractionnement de la dose d'irradiation , Radiothérapie conformationnelle/effets indésirables , Tumeurs de la vessie urinaire/radiothérapie , Sujet âgé , Sujet âgé de 80 ans ou plus , Survie sans rechute , Femelle , Humains , Mâle , Invasion tumorale , Mesure de la douleur , Dose de rayonnement , Statistique non paramétrique , Facteurs temps , Résultat thérapeutique
18.
Int. braz. j. urol ; 39(1): 77-82, January-February/2013. tab, graf
Article de Anglais | LILACS | ID: lil-670365

RÉSUMÉ

Aim To evaluate acute toxicity and symptoms palliation of a weekly hypofractionated 3DCRT schedule as radical treatment in elderly patients with organ confined bladder cancer cT1-2N0. Materials and Methods Between February 2005 and June 2011, 58 prospectively selected patients diagnosed with organ confined bladder cancer were treated with external 3DCRT (4-field arrangement). All candidates were medically inoperable, with poor performance status, and with age ranged from 75 to 88 years (median 78). A dose of 36 Gy in 6 weekly fractions was prescribed. The primary study endpoints were the evaluation of haematuria, dysuria, frequency and pain palliation as well as the acute toxicity according to the RTOG/EORTC scale: an assessment was performed at baseline, during and 3 months after radiotherapy, while the maximum reported score was taken into account. Results The gastrointestinal acute toxicities were 13/58 (22.4%) and 5/58 (5.6%), for grade I and II respectively. The genitourinary acute toxicities were 19/58 (32.7%) and 10/58 (17.2%), for grade I and II respectively. In terms of clinical outcome, 55/58 patients (94.8%) reported palliation of haematuria, while 19 out of 58 reported no change in frequency and dysuria. All patients reported significant improvement (P < 0.01) for pain, concerning the visual analogue score before and after radiotherapy. The median progression free survival was 14 months. CONCLUSIONS The incidence of patient-reported acute toxicity following weekly hypofractionated external 3DCRT is low while the symptom palliation compares very favorably with other reported outcomes. .


Sujet(s)
Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Mâle , Fractionnement de la dose d'irradiation , Radiothérapie conformationnelle/effets indésirables , Tumeurs de la vessie urinaire/radiothérapie , Survie sans rechute , Invasion tumorale , Mesure de la douleur , Dose de rayonnement , Statistique non paramétrique , Facteurs temps , Résultat thérapeutique
19.
Int Braz J Urol ; 39(6): 808-16, 2013.
Article de Anglais | MEDLINE | ID: mdl-24456773

RÉSUMÉ

OBJECTIVE: The aim of our study was to assess short and mid-term clinical efficacy of external beam radiation therapy to achieve hemostasis in patients with bladder-cancer related gross hematuria who were unfit for surgery. We also assessed hypofractionation as a possible alternative option for more severe patients. PATIENTS AND METHODS: Thirty-two patients were included for hemostatic radiation therapy, with two schedules based on Eastern Cooperative Oncology Group performance status. The standard treatment was 30 Gy in 10 fractions over 2 weeks. More severe patients underwent a hypofractionated regimen, with 20 Gy in 5 fractions over a one week period. Clinical evaluation was performed at 2 weeks and 6 months. RESULTS: At 2 weeks, 69% of patients were hematuria-free. Subgroup analysis showed that 79% of patients undergoing hypofractionated regimen were hematuria-free. A total of 54% were hematuria-free with the standard regimen. Based on tumor stage, hematuria was controlled at 2 weeks for 57% of non-muscle invasive tumors and 72% of muscle-invasive tumors. After 6 months, 69% of patients had relapsed, regardless of tumor stage or therapy schedules. CONCLUSIONS: Hemostatic radiotherapy is an effective option for palliative-care hematuria related to bladder cancer in patients unfit for surgery. Although it appears to be rapidly effective, its effect is of limited duration. Hypofractionation also seems to be an effective option; however larger cohorts and prospective trials are needed to evaluate its efficacy compared to standard schedules.


Sujet(s)
Carcinomes/radiothérapie , Hématurie/radiothérapie , Tumeurs de la vessie urinaire/radiothérapie , Sujet âgé , Sujet âgé de 80 ans ou plus , Carcinomes/complications , Femelle , Hématurie/étiologie , Humains , Soins palliatifs/méthodes , Protonthérapie/méthodes , Études rétrospectives , Statistique non paramétrique , Facteurs temps , Résultat thérapeutique , Tumeurs de la vessie urinaire/complications
20.
Int Braz J Urol ; 38(2): 144-53; discussion 153-4, 2012.
Article de Anglais | MEDLINE | ID: mdl-22555038

RÉSUMÉ

The role of radiotherapy (RT) in the treatment of urinary bladder cancer has undergone several modifications along the last decades. In the beginning, definitive RT was used as treatment in an attempt to preserve the urinary bladder; however, the results were poor compared to those of radical surgery. Recently, many protocols have been developed supporting the use of multi-modality therapy, and the concept of organ preservation began to be reconsidered. Although phase III randomized clinical studies comparing radical cystectomy with bladder preservation therapies do not exist, the conservative treatment may present low toxicity and high indexes of complete response for selected patients. The aim of this study was to review the literature on the subject in order to situate RT in the current treatment of urinary bladder cancer.


Sujet(s)
Carcinomes/radiothérapie , Tumeurs de la vessie urinaire/radiothérapie , Antinéoplasiques/usage thérapeutique , Carcinomes/traitement médicamenteux , Carcinomes/chirurgie , Cisplatine/usage thérapeutique , Association thérapeutique/méthodes , Cystectomie , Humains , Soins postopératoires , Soins préopératoires , Essais contrôlés randomisés comme sujet , Résultat thérapeutique , Tumeurs de la vessie urinaire/traitement médicamenteux , Tumeurs de la vessie urinaire/chirurgie , Incontinence urinaire/étiologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE